Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) EBT Margin (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed EBT Margin for 13 consecutive years, with 14.45% as the latest value for Q3 2025.

  • On a quarterly basis, EBT Margin rose 4514.0% to 14.45% in Q3 2025 year-over-year; TTM through Sep 2025 was 58.81%, a 12935.0% increase, with the full-year FY2024 number at 69.3%, down 216585.0% from a year prior.
  • EBT Margin was 14.45% for Q3 2025 at Theravance Biopharma, down from 279.47% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 781.22% in Q4 2022 to a low of 1589.4% in Q1 2022.
  • A 5-year average of 179.83% and a median of 91.88% in 2025 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: surged 496978bps in 2021, then crashed -103212bps in 2022.
  • Theravance Biopharma's EBT Margin stood at 422.55% in 2021, then soared by 285bps to 781.22% in 2022, then tumbled by -106bps to 48.32% in 2023, then grew by 1bps to 47.66% in 2024, then surged by 70bps to 14.45% in 2025.
  • Per Business Quant, the three most recent readings for TBPH's EBT Margin are 14.45% (Q3 2025), 279.47% (Q2 2025), and 91.88% (Q1 2025).